Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application

Stock News12-04

Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" from the National Medical Products Administration for the domestic production drug registration application of Dapagliflozin and Metformin Extended-Release Tablets.

The compound tablet of SGLT-2 inhibitor dapagliflozin and metformin hydrochloride was developed by British pharmaceutical company AstraZeneca and approved by the FDA in 2014. It was approved for marketing in China in June 2023.

SGLT-2 inhibitors work through a non-insulin-dependent mechanism by reducing glucose reabsorption in the kidneys and directly excreting glucose through urine to lower blood sugar levels. The combination of SGLT-2 inhibitors with metformin has demonstrated better glycemic control and fewer side effects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158558592?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158558592","market":"sh","top_or_hot":-1,"title":"Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application","media":"Stock News","content":"<p>Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the domestic production drug registration application of Dapagliflozin and Metformin Extended-Release Tablets.</p>\n<p>The compound tablet of SGLT-2 inhibitor dapagliflozin and metformin hydrochloride was developed by British pharmaceutical company AstraZeneca and approved by the FDA in 2014. It was approved for marketing in China in June 2023.</p>\n<p>SGLT-2 inhibitors work through a non-insulin-dependent mechanism by reducing glucose reabsorption in the kidneys and directly excreting glucose through urine to lower blood sugar levels. The combination of SGLT-2 inhibitors with metformin has demonstrated better glycemic control and fewer side effects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-04 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the domestic production drug registration application of Dapagliflozin and Metformin Extended-Release Tablets.</p>\n<p>The compound tablet of SGLT-2 inhibitor dapagliflozin and metformin hydrochloride was developed by British pharmaceutical company AstraZeneca and approved by the FDA in 2014. It was approved for marketing in China in June 2023.</p>\n<p>SGLT-2 inhibitors work through a non-insulin-dependent mechanism by reducing glucose reabsorption in the kidneys and directly excreting glucose through urine to lower blood sugar levels. The combination of SGLT-2 inhibitors with metformin has demonstrated better glycemic control and fewer side effects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1158558592","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158558592","pubTimestamp":1764835731,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300485":"赛升药业","BK0239":"医药制造","BK0046":"生物疫苗","BK0028":"国家队","BK0012":"证金概念"},"translate_title":"北京科学太阳药业（300485.SZ）达格列净二甲双胍缓释片药品注册申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300485":1},"content_text":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) announced that its subsidiary, Beijing Science Sun Biological Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the domestic production drug registration application of Dapagliflozin and Metformin Extended-Release Tablets.\nThe compound tablet of SGLT-2 inhibitor dapagliflozin and metformin hydrochloride was developed by British pharmaceutical company AstraZeneca and approved by the FDA in 2014. It was approved for marketing in China in June 2023.\nSGLT-2 inhibitors work through a non-insulin-dependent mechanism by reducing glucose reabsorption in the kidneys and directly excreting glucose through urine to lower blood sugar levels. The combination of SGLT-2 inhibitors with metformin has demonstrated better glycemic control and fewer side effects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158558592","isCrawlerRequest":true}